Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Receivables: 2014-2025

Historic Receivables for ImmunityBio (IBRX) over the last 2 years, with Sep 2025 value amounting to $33.7 million.

  • ImmunityBio's Receivables rose 587.17% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.8 million, marking a year-over-year increase of 440.72%. This contributed to the annual value of $2.4 million for FY2024, which is N/A change from last year.
  • Per ImmunityBio's latest filing, its Receivables stood at $33.7 million for Q3 2025, which was up 50.91% from $22.3 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Receivables ranged from a high of $33.7 million in Q3 2025 and a low of $2.1 million during Q2 2024.
  • For the 3-year period, ImmunityBio's Receivables averaged around $10.4 million, with its median value being $3.6 million (2023).
  • As far as peak fluctuations go, ImmunityBio's Receivables crashed by 38.05% in 2024, and later spiked by 983.98% in 2025.
  • Over the past 4 years, ImmunityBio's Receivables (Quarterly) stood at $3.2 million in 2022, then reached $3.6 million in 2023, then soared by 35.28% to $2.4 million in 2024, then surged by 587.17% to $33.7 million in 2025.
  • Its Receivables was $33.7 million in Q3 2025, compared to $22.3 million in Q2 2025 and $17.5 million in Q1 2025.